FDA delay for ph 3 trial approval, page-33

Aviza,

Difficult question to answer even with detailed broker data. I think it's a bit of a mix, there are a few small fundies that would've bought into us earlier but are now selling as we aren't meeting a lot of their mandated holding criteria. Eg be of a min. capitalisation, have lower measure in terms of ATR (Average True Range of stock price fluctuations over time - it's a like a degree of price volatility) etc.

A number of holders are trimming or getting out, they have endured the painful decline for too long.
It's unfortunate but it also doesn't mean everyone is getting out. There maybe new funds to us, there are a few holders that are adding, willing to take a chance on what positive events are hopefully to come.

We are reliant on the FDA feedback, their response to our revised protocol and dosing acceptance etc. Once we have this, I certainly think a lot of good things can follow for those that are left and have the (further) patience to see what's next.


BTW- How did you hear about PAR?

- Mozz